After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on RLAY stock, giving a Buy rating yesterday.Stay Ahead of the ...

Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2 ...

Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations, even as Biden-appointed ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...